Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Verastem Oncology priced a $250 million underwritten offering of 30.9 million common shares at $8.00, plus pre-funded warrants on roughly 312,500 shares at $7.9999. The deal is expected to close on or about October 15, 2026, with Jefferies, Guggenheim and Cantor as joint book-runners and B. Riley Securities as lead manager.
Key figures
- Deal Value Usd
- 250000000
- Offering Price
- 8
- Shares Offered
- 30937500
- Prefunded warrant price
- $7.9999
- Prefunded warrant shares
- 312503
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.